Four new data presentations, including late breaking clinical study data, underscores the value of KidneyIntelX testing in helping slow progression of chronic kidney disease in type 2 diabetes patientsLONDON and SALT LAKE CITY, June 15, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that three scientific abstracts have been accepted at the upcoming American Diabetes Association 83rd Scientific Sessions (June 23-26, 2023) in San Diego, California and another abs